We are a relatively well-known private forum and have decided to offer our proven network of labs to support the public hair loss communities. This will be a unique opportunity for everyone to access and research novel groundbreaking treatments for a lower price and earlier than it would otherwise be possible since we are dealing directly with the labs without trading companies as middle men. We are also able to practice sound quality control as we are working directly with the manufacturers. All products are third-party tested (NMR, HPLC/MS ...) to guarantee that the quality is up to industry standards. You are also encouraged to test it yourself at a third-party lab of your choice.
As some of you maybe know, our forum has held a myriad of group buys with an impeccable track record for over a decade now (Started in 2012). As previously mentioned, our forum is not only working with a single lab (or even a single reseller) but rather a whole network of labs. (Let me tell you that a single "lab" that allegedly synthesizes every hair loss compound imaginable is most definitely just a reseller buying it from different specialized labs that only synthesize a hand full of compounds).
Our first public GB will be Pyrilutamide, giving everyone affordable and early access to this exciting drug for their research. ($70/g at ≥98% purity + shipping; you will be hard-pressed to find a comparable - legitimate - offer, even in China)
For more details and to join in on this opportunity, check out this Discord server: https://discord.gg/5sbtqbR5D3
Some info about Pyrilutamide for those that haven't heard about it:
Pyrilutamide (KX-826) is a nonsteroidal antiandrogen (NSAA), a selective high-affinity silent antagonist of the androgen receptor (AR), under development by Suzhou Kintor Pharmaceuticals, as a potential first-in-class topical drug for treatment of androgenetic alopecia (Androgenetic Alopecia) and acne vulgaris in males/females. Pyrilutamide is currently in phase III clinical trials for the potential treatment of androgenetic alopecia. During previous trials, no severe adverse events were observed. The most common adverse event was mild contact dermatitis. The approximate serum half life is 13.9h with minimal systemic absorption. Pyrilutamide binds to the androgen receptor with an IC50 of 0.28uM on PSA production in LNCaP cells. (Bicalutamide IC50: 3.10uM) Preliminary results from the phase II trial showed a statistically significant increase (p<0.001) of TAHC (Target Area Hair Count) with mean changes from TAHC baseline of 22.73 (0.5% BID) and 14.75 (0.25% BID), respectively - similar to Dutasteride.
Dosing: Trial used 5mg/mL BID (twice a day)
We've done this for a very long time and know exactly what we are doing. You will get what you paid for and that's a guarantee. No underhanded tactics, coercion, bait and switch, dilution, contamination or other deceptive tactics common elsewhere.
FOR RESEARCH PURPOSES ONLY!
As some of you maybe know, our forum has held a myriad of group buys with an impeccable track record for over a decade now (Started in 2012). As previously mentioned, our forum is not only working with a single lab (or even a single reseller) but rather a whole network of labs. (Let me tell you that a single "lab" that allegedly synthesizes every hair loss compound imaginable is most definitely just a reseller buying it from different specialized labs that only synthesize a hand full of compounds).
Our first public GB will be Pyrilutamide, giving everyone affordable and early access to this exciting drug for their research. ($70/g at ≥98% purity + shipping; you will be hard-pressed to find a comparable - legitimate - offer, even in China)
For more details and to join in on this opportunity, check out this Discord server: https://discord.gg/5sbtqbR5D3
Some info about Pyrilutamide for those that haven't heard about it:
Pyrilutamide (KX-826) is a nonsteroidal antiandrogen (NSAA), a selective high-affinity silent antagonist of the androgen receptor (AR), under development by Suzhou Kintor Pharmaceuticals, as a potential first-in-class topical drug for treatment of androgenetic alopecia (Androgenetic Alopecia) and acne vulgaris in males/females. Pyrilutamide is currently in phase III clinical trials for the potential treatment of androgenetic alopecia. During previous trials, no severe adverse events were observed. The most common adverse event was mild contact dermatitis. The approximate serum half life is 13.9h with minimal systemic absorption. Pyrilutamide binds to the androgen receptor with an IC50 of 0.28uM on PSA production in LNCaP cells. (Bicalutamide IC50: 3.10uM) Preliminary results from the phase II trial showed a statistically significant increase (p<0.001) of TAHC (Target Area Hair Count) with mean changes from TAHC baseline of 22.73 (0.5% BID) and 14.75 (0.25% BID), respectively - similar to Dutasteride.
Dosing: Trial used 5mg/mL BID (twice a day)
We've done this for a very long time and know exactly what we are doing. You will get what you paid for and that's a guarantee. No underhanded tactics, coercion, bait and switch, dilution, contamination or other deceptive tactics common elsewhere.
FOR RESEARCH PURPOSES ONLY!
